Intellia reports Q3 net loss $122.2M, FDA clears NTLA-2001 Phase 3 IND for ATTR-CM

Intellia Therapeutics, Inc.

2023-Q3 EPS reported -$3.96 revenue$38,192,000

FDA cleared IND for NTLA-2001 Phase 3 MAGNITUDE trial in ATTR cardiomyopathy; on track to initiate by year-end.
Phase 1 data: median serum TTR reduction 91% in 62 patients; durable reduction at 12+ months.
NTLA-2002 Phase 2 enrollment on track to complete Q4 2023; received EMA PRIME designation for HAE.
Expanded Regeneron collaboration in neurological and muscular diseases; $30M payment expected H1 2024.
Q3 net loss $122.2M vs $113.2M YoY; cash, equivalents and marketable securities $992.5M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Intellia Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

Intellia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-061539

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.